Send to

Choose Destination
Nat Biotechnol. 2014 Apr;32(4):356-63. doi: 10.1038/nbt.2825. Epub 2014 Mar 16.

Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery.

Author information

Kymab Ltd., Babraham Research Campus, Cambridge, UK.
Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.
1] Kymab Ltd., Babraham Research Campus, Cambridge, UK. [2] Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK.


If immunized with an antigen of interest, transgenic mice with large portions of unrearranged human immunoglobulin loci can produce fully human antigen-specific antibodies; several such antibodies are in clinical use. However, technical limitations inherent to conventional transgenic technology and sequence divergence between the human and mouse immunoglobulin constant regions limit the utility of these mice. Here, using repetitive cycles of genome engineering in embryonic stem cells, we have inserted the entire human immunoglobulin variable-gene repertoire (2.7 Mb) into the mouse genome, leaving the mouse constant regions intact. These transgenic mice are viable and fertile, with an immune system resembling that of wild-type mice. Antigen immunization results in production of high-affinity antibodies with long human-like complementarity-determining region 3 (CDR3H), broad epitope coverage and strong signatures of somatic hypermutation. These mice provide a robust system for the discovery of therapeutic human monoclonal antibodies; as a surrogate readout of the human antibody response, they may also aid vaccine design efforts.

Comment in

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center